Equfina (safinamide) has been approved in South Korea as an add-on therapy to levodopa for Parkinson’s disease patients who experience “off” episodes, Eisai, which is marketing this medication in parts of Asia, announced. The approval makes South Korea the first country in Asia outside of Japan to sell…
Structural changes within alpha-synuclein can make this protein more prone to clumping — a common feature of Parkinson’s — a research group found, a discovery that might lead to ways of stopping this disease in its early stages. The study, “Extent of N-terminus exposure of monomeric alpha-synuclein…
Manus Neurodynamica, a medical technology company, has raised £750,000 in a financing round to support the rollout of NeuroMotor Pen, a digital pen with a patented sensor technology to help diagnose at early stages movement disorders like Parkinson’s disease. The funding, worth about $950,000, will also be used to…
The U.S. Food and Drug Administration (FDA) has agreed to review Adamas Pharmaceutical’s application asking that oral Gocovri (amantadine) also be approved to treat off episodes in Parkinson’s disease patients using levodopa. An FDA decision on the company’s supplemental new drug application (sNDA) is expected by Feb. 1, 2021.
People carrying gene variants that lower leucine-rich repeat kinase 2 (LRRK2) levels — an enzyme whose mutated form is one of the most common genetic causes of Parkinson’s disease — live as long as those without such variants, and show no related lung, liver or kidney damage, results of a large genetic study…
Seelos Therapeutics announced it is beginning, earlier than expected, a preclinical study into its investigational gene therapy candidate for Parkinson’s disease called SLS-004. The exact nature of this early research work was not detailed in a press release. Nerve cell damage in Parkinson’s is caused by the buildup of toxic forms…
Current or past tobacco smokers are at lower risk of developing Parkinson’s disease than lifelong non-smokers, a long-term study of doctors in the U.K. reports. How smoking might protect a person against Parkinson’s, however, remains poorly understood. The many known health risks of tobacco smoking also far exceed “any protective effect,”…
GB Sciences has been granted a patent from the U.S. Patent and Trademark Office (USPTO) covering the use of its proprietary cannabinoid-containing complex mixtures for treating Parkinson’s disease, the company announced. GB Sciences is creating a pipeline of new medicines based on cannabinoids, the pharmacologically active compounds that…
Researchers have developed short gene promoters — structures that act like switches to turn on genes — that may boost the effectiveness of gene therapies targeting the central nervous system. These promoters allow for the delivery of larger genes into the central nervous system while keeping them active for…
Zhichan powder, a traditional Chinese medicine, contains several active compounds that may be of therapeutic value in Parkinson’s disease, researchers suggest. Their study, “Network Pharmacology Analysis on Zhichan Powder in the Treatment of Parkinson’s Disease,” appeared in the journal Combinatorial Chemistry & High Throughput Screening. Parkinson’s is…
Get regular updates to your inbox.
